Minoxidil for Beard Growth: Evidence, Timeline, and What Happens When You Stop

For decades, young men with patchy cheeks, weak jawline connectors, or thin mustaches were told that facial hair density was purely a matter of genetic luck and chronological patience. However, across internet communities like Reddit's r/Minoxbeards and hair restoration forums, large numbers of men have turned to an unconventional off-label hack: applying over-the-counter topical minoxidil (traditionally marketed as Rogaine) directly to their faces to grow a fuller beard.

While telehealth platforms and beard-care brands have capitalized on this trend by selling minoxidil kits, commercial marketing often glosses over the clinical realities:

1. The Regulatory Boundary: Minoxidil is FDA-approved exclusively for androgenetic alopecia of the scalp. Every facial application of minoxidil is entirely off-label and has never been evaluated in FDA registration trials by pharmaceutical manufacturers.
2. The Controlled Trial Evidence: Despite being off-label, a real and remarkably specific human clinical trial literature exists. A landmark 2026 double-blind, randomized, placebo-controlled trial (Wattanawinitchai et al., 2026; PMID 41778417) evaluated topical 3% minoxidil in transgender men on gender-affirming hormone therapy, demonstrating a statistically significant increase in beard density of +11.16 hairs/cm² versus +0.08 hairs/cm² for placebo.
3. The "Lease vs. Purchase" Question: Unlike scalp hair loss (where stopping minoxidil predictably sheds gains back toward baseline), facial hair may behave differently: a follicle that transitions into a fully mature terminal hair is maintained by circulating androgens, so it plausibly persists after minoxidil stops. But note the evidence ceiling honestly — no study has formally followed facial-hair gains after discontinuation. The 2024 cohort study's authors explicitly state that post-cessation persistence still needs assessment, and the twin-case report's authors call it unknown. Community experience suggests fully terminalized hairs often stay while anything less regresses.
4. Facial Skin & Toxicity Risks: Applying minoxidil to facial skin carries higher rates of localized contact dermatitis (especially from liquid propylene glycol formulations), facial hypertrichosis (unwanted hair near the eyes and temples), systemic cardiovascular side effects, and lethal toxicity to domestic cats.

Understanding the controlled clinical trial data, follicular pharmacology, realistic month-by-month timelines, and safety boundaries is essential before applying any hair restoration drug to your face.

---

Direct Answer: Does Minoxidil Work for Beard Growth?

For someone evaluating topical minoxidil for facial hair:

• The Clinical Efficacy: Topical minoxidil reliably accelerates the transition of dormant or fine facial vellus follicles into thicker, pigmented hairs by stimulating microvascular perfusion and upregulating follicular sulfotransferase pathways.
• The Clinical Evidence Base: Supported by a 2026 double-blind, placebo-controlled RCT in trans men (PMID 41778417), an open-label prospective cohort study (Marinelli et al., 2024; PMID 38644453), a 2016 randomized blinded trial in cisgender men (Ingprasert et al., 2016; PMID 26893270), and a documented monozygotic twin case study (Shokravi & Zargham, 2024; PMC10894539).
• The Timeline: Expect an initial shed in weeks 2 to 6, early vellus sprouting at months 2 to 3, and visible thickening by months 4 to 6. A minimum 6-to-12-month commitment is required to allow hairs to fully terminalize.
• Permanence: The honest unknown. Mature terminal facial hairs depend on circulating androgens rather than ongoing minoxidil, which is the mechanistic argument that gains can persist after stopping — and community experience generally supports it. But no controlled trial has followed facial-hair outcomes after discontinuation. Plan for maintenance as the default, and treat anything that survives stopping as a real possibility, not a promise.
• Formulation Choice: Use 5% minoxidil foam rather than liquid solution. The liquid vehicle contains high concentrations of propylene glycol, which frequently causes severe peeling, redness, and itching on facial skin.
• Major Warnings: Strictly contraindicated in anyone under 18. Keep away from cats—minoxidil lacks a metabolic pathway in felines and is fatal even in trace amounts.

---

Is Minoxidil FDA-Approved for Beards? (The Label Reality)

A critical distinction that separates evidence-based medicine from commercial hype is the regulatory status of topical minoxidil.

According to the official FDA Over-the-Counter (OTC) drug label for topical minoxidil (DailyMed):

• The men's 5% Use statement is narrow: "to regrow hair on the top of the scalp (vertex only)" — with the women's product carrying a parallel claim for diffuse thinning on top.
• The Do Not Use list includes having "no family history of hair loss," hair loss that is "sudden and/or patchy," and being "under 18 years of age."
• Under "When using this product," the label directs: "do not apply on other parts of the body" — the sentence that makes every beard application off-label by the label's own text.

No pharmaceutical manufacturer (from the original developer Upjohn to modern generic distributors) has ever funded a formal New Drug Application (NDA) clinical trial package to clear minoxidil for facial hair enhancement.

When a dermatologist or physician discusses minoxidil for beard growth, it is conducted entirely under off-label medical discretion.

---

The Real Evidence, Rated: RCTs, Cohort Studies, and Twin Data

Despite the lack of pharmaceutical sponsorship, academic dermatology departments have independently evaluated topical minoxidil for facial hair growth in controlled clinical settings.

1. The Landmark 2026 Double-Blind RCT: Wattanawinitchai et al.

The highest-quality evidence in the literature was published in 2026 by researchers at Ramathibodi Hospital, Mahidol University (J Dermatolog Treat 2026; PMID 41778417; Clinical Trial TCTR20220205004).

• Trial Protocol: A randomized, double-blind, placebo-controlled clinical trial evaluating 69 transgender men on stable gender-affirming hormone therapy (testosterone). Participants were randomized to apply 3% minoxidil lotion or an identical placebo vehicle to their facial hair region twice daily for 12 weeks.
• Primary Quantitative Endpoints:
  1. Beard Hair Density: The 3% minoxidil group achieved a mean increase of +11.16 hairs per cm², compared to just +0.08 hairs per cm² in the placebo group (P = 0.01).
  2. Hair Shaft Diameter: Mean hair diameter increased by +5.37 μm in the minoxidil group, compared to a slight reduction of -0.33 μm in the placebo group (P = 0.01).
  3. Mustache Density: Mustache density increased by +18.45 hairs per cm² with minoxidil versus +1.74 hairs per cm² with placebo (P = 0.003).
• Quality of Life & Safety: Patients in the minoxidil arm demonstrated significant improvements in the Dermatology Life Quality Index (DLQI) and high satisfaction scores. Adverse events were mild, transient, and did not differ significantly between the minoxidil and placebo arms.

2. The 2024 Prospective Cohort Study: Marinelli et al.

Published in the Journal of Endocrinological Investigation (J Endocrinol Invest 2024; PMID 38644453), this study evaluated the prospective impact of topical minoxidil over a 6-month timeframe in 16 trans men initiating facial hair treatment compared to 16 matched controls on testosterone alone.

• Results: Modified Ferriman-Gallwey (FGm) scores for facial hair increased significantly by month 6 (upper lip median score rose to 3.5 from 2.0 at baseline; chin score rose to 4.0 from 1.0; P ≤ 0.002).
• Predictors of Response: In multivariable regression, pre-existing subclinical hirsutism was a powerful independent predictor of achieving a dense, full beard (Odds Ratio 15.22), showing that baseline follicular presence strongly dictates the speed and quality of response.
• The Caveat the Authors Themselves Flag: the study's conclusion states that further studies "will be necessary to assess whether the obtained improvements will persist after discontinuing the medication" — the persistence question is open even in the best-controlled facial-hair data.

3. The 2016 Cisgender Blinded Trial: Ingprasert et al.

The earliest randomized, double-masked, placebo-controlled study evaluating facial hair enhancement in cisgender men was published as a 2-page brief report in the Journal of Dermatology (J Dermatol 2016; PMID 26893270). Forty-eight Thai men aged 20 to 60 applied 3% minoxidil lotion or vehicle to the chin and jawline twice daily for 16 weeks (46 completed). The minoxidil group showed a significantly higher global photographic score at week 16 (P = 0.002) and a greater increase in hair counts (5.00 vs 0.35), with patient-rated improvement also favoring treatment; hair diameter did not change significantly.

4. The Identical Twin Experiment: Shokravi & Zargham (2024)

Published in SAGE Open Medical Case Reports (PMC10894539; PMID 38404498), this report documented a striking natural human experiment: a pair of identical (monozygotic) male twins with similarly sparse, patchy facial hair. The treated twin applied about 1.5 g (three-quarters of a cap) of 5% minoxidil foam once daily to his beard and mustache for over a year — photographed at 16 months — while the other twin used nothing. The treated twin showed clearly greater beard and mustache density and hair count on standardized photographs (taken 10 days after shaving). Notably, he started on the liquid formulation but switched to foam within three weeks because of dry, flaky skin — a real-world confirmation of the vehicle-irritation problem discussed below. Side effects included mild dryness and hypertrichosis on the ears, forehead, chest, and arms. The report contains no post-cessation data (the twin kept using it), and its authors state that whether facial-hair gains reverse after stopping — as scalp gains do — remains unknown.

---

Why the Best Trials Are in Trans Men (and What It Means for Cisgender Readers)

A crucial question for critical readers is why the most robust randomized controlled trials were conducted in transgender men rather than cisgender men, and how those results translate across populations.

               [The Hormonal & Pharmacologic Synergy Framework]

     Systemic Androgens (Testosterone / DHT)       Topical Minoxidil (Off-Label)
  ┌───────────────────────────────────────────┐ ┌─────────────────────────────────┐
  │ Binds nuclear androgen receptors in       │ │ Upregulates sulfotransferase    │
  │ facial dermal papilla cells               │ │ (SULT1A1) -> Minoxidil sulfate  │
  │ • Transcribes growth factors (IGF-1)      │ │ • Opens ATP-sensitive K+ channels│
  │ • Primes follicle for terminal switch     │ │ • Enhances microvascular flow   │
  └─────────────────────┬─────────────────────┘ └────────────────┬────────────────┘
                        │                                        │
                        └───────────────────┬────────────────────┘
                                            │
                                            ▼
                          Accelerated Terminal Conversion
                        (Thick, Pigmented Beard Follicles)

The Biology of Facial vs. Scalp Hair

Hair follicles on the scalp and face respond in diametrically opposite ways to androgenic hormones:

• On the Scalp: Dihydrotestosterone (DHT) binds to genetically sensitive androgen receptors, triggering follicular miniaturization, shortened anagen phases, and androgenetic alopecia (pattern hair loss; see our review of the androgenetic alopecia treatment ladder).
• On the Face: Androgens (Testosterone and DHT) act as growth promoters. During puberty, rising testosterone levels bind to androgen receptors in facial dermal papilla cells, upregulating insulin-like growth factor-1 (IGF-1) and instructing microscopic vellus hair follicles to transform into coarse, thick, pigmented terminal beard hairs.

The Population-Transfer Caveat

Transgender men initiating gender-affirming hormone therapy represent an ideal clinical model because their facial follicles are actively undergoing androgen-primed maturation. Minoxidil acts as an accelerator, multiplying the rate at which follicles transition from vellus to terminal.

For cisgender men:

1. If you have normal circulating testosterone and dormant vellus follicles: minoxidil plausibly stimulates those existing follicles toward terminalization — the mechanism is the same — but the blinded effect sizes above were measured in androgen-primed follicles, so a somewhat smaller response would not be surprising.
2. If you have a true genetic bare zone (Zero Follicles): If genetics dictate that you have zero hair follicles in a specific square centimeter of cheek skin, minoxidil cannot magically generate new biological follicles out of bare dermis. It can only stimulate and hypertrophy pre-existing follicles.
3. If you are under age 25: Many young men experience natural beard densification well into their late 20s as androgen receptors mature. Starting a daily drug regimen at age 19 may simply accelerate what nature would have delivered at age 24.

---

The Follicular Mechanism: Why Facial Gains Can Stay When Scalp Gains Fade

One of the most persistent debates around beard minoxidil is whether the results are permanent.

To answer this, we must examine the difference between a lease (scalp minoxidil) and a purchase (facial minoxidil).

The Vellus-to-Terminal Transition

Every human facial hair exists in one of three distinct developmental stages:

1. Vellus Hair: Microscopic, non-pigmented, short, soft "peach fuzz." The root sits shallowly in the upper papillary dermis.
2. Transitional Hair: Intermediate hairs that have begun to grow longer and slightly darker under minoxidil stimulation. However, the dermal papilla remains small, and the hair bulb has not fully anchored into the deep subcutaneous fat.
3. Terminal Hair: Coarse, thick, deeply pigmented hairs with an established microvascular supply and a deep root. These hairs are fully androgen-dependent.

                     [The 3 Stages of Beard Hair Maturation]

        Stage 1: Vellus              Stage 2: Transitional           Stage 3: Terminal
     ┌──────────────────┐           ┌───────────────────┐          ┌───────────────────┐
     │ • Fine peach fuzz│           │ • Longer & darker │          │ • Thick, wire-like│
     │ • Shallow root   │ ──[Minox]─► • Intermediate root ──[Minox]─► • Deep subcutaneous│
     │ • Unpigmented    │           │ • Immature bulb   │          │   bulb & pigment  │
     └──────────────────┘           └───────────────────┘          └───────────────────┘
                                              │                              │
                                     [If stopped now]               [If stopped now]
                                              ▼                              ▼
                                     SHEDS BACK TO VELLUS        MAY PERSIST (unproven
                                                                   in controlled trials)

The Mechanism of Action

Topical minoxidil is converted by follicular sulfotransferase enzymes (SULT1A1) into minoxidil sulfate, its active metabolite (for a full enzymatic breakdown, see our analysis of minoxidil foam vs solution).

Minoxidil sulfate opens ATP-sensitive potassium (K_ATP) channels in vascular smooth muscle and follicular cells:

• It induces localized microvascular vasodilation, increasing blood flow, oxygen, and nutrient delivery to the dermal papilla.
• It directly upregulates vascular endothelial growth factor (VEGF) and prostaglandin E2 (PGE2), promoting cell survival.
• It shortens the dormant telogen (resting) phase and prolongs the active anagen (growth) phase, forcing resting follicles into robust growth cycles.

The Stopping Rule

• If you stop minoxidil while hairs are still in the transitional stage (months 1 to 4): The follicular stimulus is removed before the follicle has achieved structural autonomy. The transitional hairs are expected to shed over the subsequent 8 to 16 weeks, reverting to fine vellus fuzz.
• If you maintain minoxidil until hairs achieve full terminalization (typically 6 to 12 months): The follicle's maintenance shifts to circulating androgens — that is the mechanistic argument for persistence, and community experience plus the twin report's authors' informal accounts support it. But no controlled trial has verified it. The honest expectation: fully terminal hairs often persist, anything less regresses. Commit to the 6-to-12-month assessment window and treat post-stopping retention as a real possibility, not a guarantee.

---

Month-by-Month Timeline: What to Expect

Understanding the biological timeline prevents premature discontinuation due to common early side effects like shedding or slow initial progress.

                    [Month-by-Month Beard Minoxidil Timeline]

  Month 1                 Months 2 to 3           Months 4 to 6           Months 6 to 12+
 ┌──────────────────┐    ┌──────────────────┐    ┌──────────────────┐    ┌──────────────────┐
 │ Telogen Shedding │───►│ Vellus Explosion │───►│ Transitional     │───►│ Terminal Density │
 │ & Skin Dryness   │    │ (Fine peach fuzz │    │ Darkening &      │    │ & Consolidation  │
 │ (Weeks 2 to 6)   │    │  fills patches)  │    │ Thickening       │    │ (Permanent gains)│
 └──────────────────┘    └──────────────────┘    └──────────────────┘    └──────────────────┘

Month 1: The Initial Shed and Skin Adjustment

• The "Minoxidil Shed": Between weeks 2 and 6, many users experience a sudden increase in hair shedding on their face (and occasionally mild shedding on the scalp). This is a normal physiological sign: minoxidil accelerates the exit of resting telogen hairs to make room for new, thicker anagen shafts.
• Skin Adaptation: Mild redness, localized itching, and skin dryness are common as the facial epidermis adapts to the vehicle.

Months 2 to 3: The Vellus Explosion

• Patches and bare spots begin filling with hundreds of fine, translucent, non-pigmented vellus hairs.
• Under direct sunlight or flashlight inspection, these hairs are clearly visible as a dense peach fuzz coating the jawline and cheeks.
• Shaving or trimming during this phase does not harm the follicles or slow progress; hair grows from the subterranean root, not the dead shaft.

Months 4 to 6: Transitional Darkening

• Vellus hairs begin thickening and absorbing melanin, transforming into darker, coarser transitional hairs.
• Beard connectors between the mustache and chin begin establishing visible definition.
• Density becomes noticeable in normal ambient lighting without close inspection.

Months 6 to 12: Terminal Consolidation & Evaluation

• Transitional hairs complete their transition into coarse, wire-like terminal beard hairs with deep follicular roots.
• By month 12, maximal genetic coverage has typically been achieved.
• At this stage, some users taper toward less-frequent application rather than stopping abruptly to see which hairs hold. There is no trial-supported taper schedule — if you go this route, make it a judgment call with a prescriber rather than a forum protocol.

---

Formulation Science: 5% Foam vs. 5% Liquid on Facial Skin

Choosing the right formulation is significantly more critical on the face than on the scalp.

Why Liquid Solution Causes Severe Facial Peeling

Standard 5% minoxidil liquid relies on propylene glycol (PG) as a solvent and penetration enhancer. While scalp skin is thick and rich in sebaceous glands, facial skin (especially along the jawline and neck) is significantly more sensitive.

Propylene glycol frequently induces allergic and irritant contact dermatitis, presenting as:

• Severe flaking and white powdery scaling across the beard area.
• Intense burning, erythema, and eczema-like plaques.
• Impaired stratum corneum barrier function (see damaged skin barrier repair).

Why Foam is Superior for Facial Application

Minoxidil 5% foam replaces propylene glycol with a soothing emulsion base of cetyl alcohol, stearyl alcohol, and glycerin. It dries within 3 to 5 minutes, leaves zero greasy residue, and causes dramatically lower rates of facial irritation. For any patient applying minoxidil to the face, foam is the recommended first-line vehicle.

---

Safety Boundaries: Side Effects, Contraindications, and Feline Toxicity

Because minoxidil is a potent vasodilatory pharmaceutical, applying it to the vascular facial region requires strict adherence to safety protocols.

                    [Perioral & Facial Safety Risk Map]

                        Systemic Absorption Risk (≈1.4% of applied dose)
                        ├── Vasodilation & Hypotension (Lightheadedness)
                        ├── Reflex Tachycardia & Palpitations
                        └── Peripheral Fluid Retention (Ankle/Facial edema)
                                   │
     Accidental Transfer ──────────┼──────── Localized Cutaneous Effects
     ├── Upper cheek hypertrichosis│         ├── Irritant Contact Dermatitis
     ├── Forehead / temple fuzz    │         ├── Xerosis & Flaking (Liquid PG)
     └── Pillowcase cross-transfer │         └── Initial Telogen Shedding
                                   │
                        Domestic Pet Toxicity (FATAL)
                        └── Cats lack glucuronyl transferase ──► Lethal pulmonary edema

1. Facial and Systemic Adverse Effects

2. The Lethal Cat Toxicity Warning (Non-Negotiable)

Domestic cats (Felis catus) have a unique genetic deficiency: they completely lack the hepatic glucuronyl transferase (UGT1A6/UGT1A9) enzyme required to metabolize and clear minoxidil.

• Even microscopic exposure—such as a cat licking a minoxidil droplet from a countertop, rubbing its face against a user's treated beard, or sleeping on a pillowcase contaminated with wet minoxidil—can cause acute fatal pulmonary edema, severe hypotension, pleural effusion, and cardiac failure within 12 to 48 hours.
• If you own a cat: Apply minoxidil strictly in a closed bathroom, wash your hands with soap, ensure the product is 100% dry before leaving the room, wash pillowcases frequently, and never allow your cat to lick your face.

3. Absolute Contraindications

• Under 18 Years of Age: Strictly contraindicated. Teenage endocrine systems and facial follicles are still undergoing natural developmental changes.
• Pregnancy & Partner Exposure: The OTC label directs users to ask a doctor before use if pregnant or breastfeeding ("may be harmful if used when pregnant or breast-feeding"), and oral minoxidil carries animal-data warnings — historically labeled pregnancy Category C before letter categories were retired. Systemic exposure from topical use is small but not zero, which is why male users living with pregnant partners should avoid close skin-to-skin facial contact until the product has thoroughly dried and any residue is washed off.
• Pre-Existing Cardiovascular Disease: Patients with cardiac arrhythmias, coronary artery disease, or baseline hypotension should avoid off-label minoxidil.
• Active Facial Dermatitis or Open Wounds: Never apply minoxidil over active acne cysts, eczema, or open skin abrasions; broken skin dramatically increases systemic vascular absorption.

What About Combining Minoxidil with Microneedling?

While scalp microneedling has strong clinical trial evidence as an adjunct for pattern hair loss (see our review on microneedling for hair growth evidence), there are zero published randomized controlled trials evaluating microneedling for beard growth.

Home microneedling (dermarolling) on facial skin creates micro-tears that risk bacterial folliculitis, scarring, and increased systemic absorption of any drug applied over the injured skin. There is no facial data supporting any specific depth or timing protocol — if a clinician recommends combining the two for the face, follow their protocol rather than forum instructions.

---

How Minoxidil Compares with a Beard Transplant

If topical minoxidil fails to achieve your desired density after 12 months of consistent use, the primary surgical alternative is an autologous beard transplant.

1. When Minoxidil Wins: Minoxidil is the ideal, non-invasive, low-cost first-line intervention for young men with general thinning, slow growth, or diffuse vellus coverage who want to see their full genetic potential without surgery.
2. When a Beard Transplant Wins: A surgical beard transplant via Follicular Unit Extraction (FUE; see our detailed guide on beard transplant graft counts, survival, and cost) is the only permanent solution for:
   • True genetic bare zones where zero hair follicles exist.
   • Traumatic scarring (burns, acne scars, or surgical scars) that destroyed the native hair follicles.
   • Patients who cannot tolerate topical minoxidil due to cardiovascular side effects or severe contact allergies.

---

Frequently Asked Questions

Does minoxidil really work for beard growth?

Yes — it measurably increases facial-hair density and diameter in controlled trials, including a 2026 double-blind randomized placebo-controlled trial (+11.16 hairs/cm² vs +0.08 for placebo). The caveat is population: the best-controlled data come from trans men on testosterone therapy, so cisgender readers should expect a possibly smaller effect.

How long does it take to grow a beard with minoxidil?

Most users notice initial vellus peach fuzz between weeks 8 and 12 (months 2 to 3). Visible darkening and transitional hair thickening occur between months 4 and 6. A full 6 to 12 months of consistent daily application is required to allow hairs to fully terminalize.

Is beard growth from minoxidil permanent?

Partially, probably — and it is the least-settled question in this entire article. The mechanism (terminal facial hairs are maintained by androgens, not minoxidil) and community experience both suggest fully terminalized hairs can persist after stopping, and the 2024 twin-report authors note informal accounts support that. But no controlled trial has followed users after discontinuation, and the 2024 cohort study's authors explicitly state persistence needs further study. Anything that has not fully terminalized will regress.

Can I use 5% minoxidil on my face, or only 2%?

In clinical trials, both 3% and 5% formulations have been evaluated. While 5% liquid is common, 5% foam is strongly recommended for facial application because it is formulated without propylene glycol, eliminating the severe skin flaking, redness, and contact dermatitis caused by liquid formulas.

Does beard minoxidil affect testosterone or hormonal balance?

No. Minoxidil is a potassium-channel opener and vasodilator, not an anti-androgen or hormone modulator. It does not alter systemic testosterone, DHT, or estrogen levels.

Why is my face itchy and flaky, and can I fix it?

Flaking and itching are almost always caused by propylene glycol in liquid minoxidil solutions. Switch immediately to 5% minoxidil foam and apply a hydrating ceramide-based moisturizer 30 to 45 minutes after the foam has completely dried.

Is minoxidil safe for cats?

NO. Minoxidil is extremely toxic and frequently fatal to cats. Felines lack the liver enzyme needed to metabolize minoxidil. Even microscopic ingestion from licking your face, touching a treated beard, or sleeping on a contaminated pillowcase can cause fatal heart failure and pulmonary edema.

---

Sources

• DailyMed — Minoxidil Topical Aerosol (Foam) 5% OTC Label (example listing; Drug Facts wording as quoted): https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=869ce741-3094-4123-9059-0669f3591b2f
• PubMed — Efficacy and Safety of Topical 3% Minoxidil for Facial Hair Enhancement in Transmen: A Randomized, Double-Blind, Placebo-Controlled Trial (J Dermatolog Treat 2026; PMID 41778417): https://pubmed.ncbi.nlm.nih.gov/41778417/
• PubMed — Efficacy of Topical Minoxidil in Enhancing Beard Growth in Transgender AFAB Individuals on GAHT (J Endocrinol Invest 2024; PMID 38644453): https://pubmed.ncbi.nlm.nih.gov/38644453/
• PubMed Central — Facial Hair Enhancement with Minoxidil: An Off-Label Use in Identical Twins (SAGE Open Med Case Rep 2024; PMC10894539): https://pmc.ncbi.nlm.nih.gov/articles/PMC10894539/
• PubMed — Efficacy and Safety of Minoxidil 3% Lotion for Beard Enhancement: A Randomized, Double-Masked, Placebo-Controlled Study (J Dermatol 2016; PMID 26893270): https://pubmed.ncbi.nlm.nih.gov/26893270/
• PubMed — Minoxidil and Its Use in Hair Disorders: A Review (Drug Des Devel Ther 2019; PMID 31496654): https://pubmed.ncbi.nlm.nih.gov/31496654/
• StatPearls — Minoxidil (Mechanism of Action, Pharmacology, Adverse Effects): https://www.ncbi.nlm.nih.gov/books/NBK482378/
• PubMed — Topical Minoxidil Exposures and Toxicoses in Dogs and Cats: 211 Cases (2001–2019) (J Am Anim Hosp Assoc 2021; PMID 34370845): https://pubmed.ncbi.nlm.nih.gov/34370845/